Characterizing Anti-HER2 Antibodies with a Combined Platform Approach
Antibody-based therapeutics are helping patients across a wide range of disease areas, from cancer, such as Rituximab treatment of CD20-positive non-Hodgkin's lymphomas, to infectious diseases like SARS-CoV-2 and HIV. Conventional techniques used in antibody discovery workflows are often limited due to low-throughput sample acquisition, large sample volume requirements, and challenges around analyzing complex datasets. The development of novel antibody therapeutics relies on high-throughput technologies with powerful analysis capabilities that can reliably screen and profile drug candidates.
View to Watch On-Demand
Scientist, BioAnalytics
Sartorius
Kirsty McBain is a Scientist in the BioAnalytics applications group at Sartorius where she is involved in research and development of novel applications for the iQue® advanced flow cytometry platform.She has supported a number of the immuno-oncology campaigns that are used to exemplify how Sartorius technology can be applied to the drug discovery process. Kirsty obtained a master’s degree in Biochemistry at the University of Bristol before joining Sartorius in 2019.
Senior Manager, Applications
SartoriusDavid is a Senior Manager of Applications at Sartorius, focused on Octet label-free detection platforms and applications. In this role, he leads a team of Applications Managers and is responsible for the strategic direction of the GMP/GxP and bioprocessing vertical markets.David started out as a Field Applications Scientist in 2011 and transitioned to the marketing applications team in 2015. Prior to this, David worked as a Senior Development Scientist, R&D department, at Beckman Coulter where he was involved in the development and validation of protein and antibody conjugate chemistries. David obtained his Ph.D. in Protein Chemistry from Tulane University, New Orleans.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.